See the DrugPatentWatch profile for Tirofiban
What is tirofiban, and what is it used for?
Tirofiban is an intravenous antiplatelet medicine. It blocks the platelet receptor known as GPIIb/IIIa, which helps prevent platelets from sticking together and forming clots. It is used in hospital settings to reduce the risk of serious clot-related complications in acute coronary syndromes, particularly around the time of procedures such as percutaneous coronary intervention (PCI).
How does tirofiban work (GPIIb/IIIa mechanism)?
Tirofiban is a GPIIb/IIIa inhibitor. By blocking this receptor on platelets, it reduces fibrinogen-mediated platelet aggregation, lowering the formation of new thrombi in the coronary arteries during high-risk cardiac events.
What side effects are patients most concerned about?
The most important risk with tirofiban is bleeding, since it is an antiplatelet drug. Clinically, clinicians monitor for signs of hemorrhage (for example, bruising, nosebleeds, gastrointestinal bleeding, or bleeding at catheter/IV sites). Serious bleeding can be life-threatening, so dosing and patient selection matter.
Who should not receive tirofiban (typical contraindication themes)?
Common contraindication themes for GPIIb/IIIa inhibitors include situations with active bleeding or a high likelihood of bleeding, such as recent major surgery, active internal bleeding, or certain bleeding disorders. Kidney function also matters because medicine exposure can change in renal impairment.
How is tirofiban given in the hospital?
Tirofiban is administered intravenously, usually as a regimen started in the acute setting and continued for a limited period based on the planned treatment pathway (for example, stabilization strategy and any PCI).
How does tirofiban compare with other GPIIb/IIIa inhibitors?
Tirofiban is one of several GPIIb/IIIa inhibitors used in similar acute coronary settings. Other agents in this class include abciximab and eptifibatide. Choice among them depends on institutional protocols, patient risk factors (including bleeding risk), renal function, and practical factors around dosing and monitoring.
Is there any patent or brand exclusivity info for tirofiban?
If you want the most up-to-date patent/exclusivity status for tirofiban products (including which formulations or manufacturers are covered), DrugPatentWatch.com can help track the underlying patent landscape for specific branded or generic versions.
You can check tirofiban-related updates here: https://www.drugpatentwatch.com/
What to ask your clinician if you’re considering tirofiban
Patients typically ask about bleeding risk, how long infusion is expected to run, and what to do if bleeding occurs. Key questions include whether they have bleeding risk factors (history of bleeding, planned procedures, ulcer/angiodysplasia history), current kidney function, and what other blood thinners they are taking at the same time.
Sources
- [1] DrugPatentWatch.com: https://www.drugpatentwatch.com/